Bellerophon Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Bellerophon is a clinical-stage biotherapeutics firm that researches and commercializes novel therapies for the treatment of cardiac diseases. Read more

Fabian Tenenbaum's photo - CEO of Bellerophon Therapeutics

CEO

Fabian Tenenbaum

CEO Approval Rating

88/100

Founded:

2009

Status:

PublicNASDAQBLPH

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Renova Therapeutics is one of Bellerophon Therapeutics's top rivals. Renova Therapeutics's headquarters is in Carlsbad, California, and was founded in 2009. Like Bellerophon Therapeutics, Renova Therapeutics also competes in the Biotechnology industry. Renova Therapeutics generates 254% of Bellerophon Therapeutics's revenue.

Covis Pharma has been one of Bellerophon Therapeutics's top competitors. Covis Pharma was founded in 2011 in Baarn, Utrecht. Covis Pharma operates in the Pharmaceuticals industry. Covis Pharma generates $51.5M more revenue than Bellerophon Therapeutics.

uniQure is one of Bellerophon Therapeutics's top competitors. uniQure was founded in Amsterdam, Noord-Holland} in 1998. Like Bellerophon Therapeutics, uniQure also works within the Biotechnology field. Compared to Bellerophon Therapeutics, uniQure generates $345.6K less revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Cerenis a competitor of Bellerophon Therapeutics?

Quarterly and Annual Revenue

Coming soon for Bellerophon Therapeutics!

Annual Revenue

$5.5M

Bellerophon Therapeutics's revenue is the ranked 10th among it's top 10 competitors. The top 10 competitors average 30.9M.

Acquisitions

No recent acquisitions found related to Bellerophon Therapeutics

Bellerophon Therapeutics Funding History

$60M$86.4M$101.7M

Since Bellerophon Therapeutics was founded in 2009, it has participated in 4 rounds of funding. In total Bellerophon Therapeutics has raised $101.7M. Bellerophon Therapeutics' last funding round was on Mar 2020 for a total of $15.3M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Mar 2020
$15.3M
-
Equity
Sep 2017
$23.4M
-
Private Placement
May 2017
$3M
-
IPO
Feb 2015
$60M

Total Funding: $101.7M

Since Bellerophon Therapeutics was founded in 2009, it has participated in 4 rounds of funding. In total Bellerophon Therapeutics has raised $101.7M. Bellerophon Therapeutics' last funding round was on Mar 2020 for a total of $15.3M

Investments

No recent investments found related to Bellerophon Therapeutics

Bellerophon Therapeutics News

June 29, 2020BioSpace

Bellerophon Therapeutics Added to Russell 3000 and Microcap Indexes

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on de... See more »
May 18, 2020BioSpace

Bellerophon Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Registered Direct Offering

Bellerophon Therapeutics, Inc. announced the pricing of offerings for an aggregate of 3,076,923 share... See more »
April 17, 2020DirectorsTalk Interviews

Bellerophon Therapeutics - Consenus Indicates Potential 151.5% Upside

Bellerophon Therapeutics with ticker code (BLPH) now have 3 analysts covering the stock. The analyst ... See more »
April 15, 2020DirectorsTalk Interviews

Bellerophon Therapeutics - Consenus Indicates Potential 165.9% Upside

Bellerophon Therapeutics with ticker code (BLPH) have now 3 analysts covering the stock. The analyst ... See more »
April 9, 2020NJB Magazine

Bellerophon Submits Investigational New Drug Application

Warren-based Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company focused on deve... See more »
April 8, 2020MarketScreener

Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

(marketscreener.com) WARREN, N.J., April 08, 2020 -- Bellerophon Therapeutics, Inc. , a clinical-stag... See more »

Bellerophon Therapeutics Press Releases

March 30, 2020GlobeNewswire

Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a cli... See more »
March 10, 2020GlobeNewswire

Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis

WARREN, N.J., March 10, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bell... See more »
December 17, 2019GlobeNewswire

Bellerophon Announces Positive Top-line Results from Cohort 2 of Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity... See more »
August 1, 2019GlobeNewswire

Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Initiation of Pivotal Cohort 3 Anticipated in Q1 2020Initiation of Pivotal Cohort 3 Anticipated in Q1... See more »
May 9, 2019GlobeNewswire

Bellerophon Provides Business Update and Reports First Quarter 2019 Financial Results

WARREN, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Beller... See more »
March 14, 2019GlobalNewswire

Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

WARREN, N.J., March 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bell... See more »
January 22, 2019StreetInsider

Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

WARREN, N.J., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Belle... See more »

Headquarters

184 Liberty Corner Road Suite 302

Warren, New Jersey07059

1-908-574-4770

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Bellerophon is a clinical-stage biotherapeutics firm that researches and commercializes novel therapies for the treatment of cardiac diseases. Bellerophon Therapeutics was founded in 2009. Bellerophon Therapeutics' headquarters is located in Warren, N...

CEO

Bellerophon Therapeutics's CEO, Fabian Tenenbaum, currently has an approval rating of 88%. Bellerophon Therapeutics's primary competitors are Renova Therapeutics, Covis Pharma & uniQure.

Website

bellerophon.com

Frequently Asked Questions about Bellerophon Therapeutics

  1. When was Bellerophon Therapeutics founded?

    Bellerophon Therapeutics was founded in 2009
  2. Who is Bellerophon Therapeutics's CEO?

    Bellerophon Therapeutics's CEO is Fabian Tenenbaum
  3. How much revenue does Bellerophon Therapeutics generate?

    Bellerophon Therapeutics generates $5.5M in revenue
  4. How much funding does Bellerophon Therapeutics have?

    Bellerophon Therapeutics has historically raised $101.7M in funding
  1. Where is Bellerophon Therapeutics's headquarters?

    Bellerophon Therapeutics's headquarters is in Warren New Jersey, USA
  2. How many employees does Bellerophon Therapeutics have?

    Bellerophon Therapeutics has 17 employees
  3. What sector does Bellerophon Therapeutics operate in?

    Bellerophon Therapeutics is in Biotechnology
  4. Who are Bellerophon Therapeutics's competitors?

    Bellerophon Therapeutics's top competitors are Renova Therapeutics, Covis Pharma, uniQure